Ablation of Plasma Prekallikrein Decreases LDL Cholesterol by Stabilizing LDL Receptor and Protects against Atherosclerosis

Conclusions: PK regulates circulating cholesterol levels through binding to LDLR and inducing its lysosomal degradation. Ablation of PK stabilizes LDLR, decreases LDL cholesterol and prevents atherosclerotic plaque development. This study suggests that PK is a promising therapeutic target to treat ASCVD.PMID:35189703 | DOI:10.1161/CIRCULATIONAHA.121.056491

Source: Circulation - February 22, 2022 Category: Cardiology Authors: Jin-Kai Wang Yang Li Xiao-Lu Zhao Yuan-Bin Liu Jing Tan Yu-Ying Xing Dilare Adi Yong-Tao Wang Zhen-Yan Fu Yi-Tong Ma Song-Mei Liu Yong Liu Yan Wang Xiong-Jie Shi Xiao-Yi Lu Bao-Liang Song Jie Luo Source Type: research